【原创】自己总结的RNAi干预的癌基因(75条) 大家一起来补全好吗
丁香园论坛
1501
自己总结的RNAi干预的癌基因 75条(有部分重复) 大家一起来补全吧 最近在考虑做哪个基因 所以顺便总结了一下 大家多提意见
AML1/MTG8 (205)
APE1 #3
ATF2 #3
Bax (202)
bcl-2 Antiapoptotic Esophageal adenocarcinoma
BCL-2,xIAP(138, 213)
BCR-AbL (136, 137)
B-raf Serine/threonine kinase Malignant melanoma
BRAF(V599E) (206)
Brk (207)
CDK-2 (138)
CEACAM6 #2 #4
COX-2 #8
c-raf #8
c-Kit Signal transduction Gastrointestinal
CSF-1, CSF-1 receptor (c-fms)
CXCR4 (163)
Cyclin E
Cyclin E Cell-cycle control Hepatocarcinoma
EGFR
EGFR (209, 210)
EphA2 (203)
EphA2 receptor tyrosine kinase
Epstein-Barr virus (EBV) (208)
EWS/Fli-1 #3
FAK
FAS/Her2 Fatty acid synthase Breast-MDA-MB-231
FGF-4 #4
Fatty acid synthase (FASE) (211)
Focal adhesion kinase (FAK) (140)
Gp210 Nuclear pore assembly Adenocarcinoma (Hela cells)
Hec1 Chromosomal segregation
Her2/neu #3
HPV E6 (143)
HPV E6/E7
H-Ras (138)
H-ras (wild-type and V12 mutant)
IGF-1R
K-Ras (58)
K-ras (V12) mutant
livin Antiapoptotic Adenocarcinoma
Livin/ML-IAP/KIAP(212)
MAPK #3
Matrix metalloproteinase (204)
MDM-2 (138)
MDR (142)
MDR Multidrug resistance Adenocarcinoma (Hela cells)
MMP-9,cathepsin B
MYC #3
NFκB p65
Nox1 Superoxide-generating oxidase Transformed NRK cellsa
NPM-ALK (218)
p53 #3
Philadelphia chromosome Chronic myeloid leukemia
PKC-α (138)
PLK 1
PLK1 (214)
Rho C Cell motility Metastasis
Ribonucleotide reductase Gemcitabine resistance Hepatic metastasis
RRM2
S100A10 (216)
STAT3 (217)
Survivin
survivin Antiapoptotic Adenocarcinoma (Hela cells)
Telomerase (215)
TEL-PDGFbeaR #3
TEL-PDGFβR
TGF-β (138)
u-PA #3
VEGF
VEGF (53, 138)
β-Catenin
Skp-2 #4
P110a,P110b of PI 3 kinase #8
Wt1,Pax2,Wnt4 #8
AML1/MTG8 (205)
APE1 #3
ATF2 #3
Bax (202)
bcl-2 Antiapoptotic Esophageal adenocarcinoma
BCL-2,xIAP(138, 213)
BCR-AbL (136, 137)
B-raf Serine/threonine kinase Malignant melanoma
BRAF(V599E) (206)
Brk (207)
CDK-2 (138)
CEACAM6 #2 #4
COX-2 #8
c-raf #8
c-Kit Signal transduction Gastrointestinal
CSF-1, CSF-1 receptor (c-fms)
CXCR4 (163)
Cyclin E
Cyclin E Cell-cycle control Hepatocarcinoma
EGFR
EGFR (209, 210)
EphA2 (203)
EphA2 receptor tyrosine kinase
Epstein-Barr virus (EBV) (208)
EWS/Fli-1 #3
FAK
FAS/Her2 Fatty acid synthase Breast-MDA-MB-231
FGF-4 #4
Fatty acid synthase (FASE) (211)
Focal adhesion kinase (FAK) (140)
Gp210 Nuclear pore assembly Adenocarcinoma (Hela cells)
Hec1 Chromosomal segregation
Her2/neu #3
HPV E6 (143)
HPV E6/E7
H-Ras (138)
H-ras (wild-type and V12 mutant)
IGF-1R
K-Ras (58)
K-ras (V12) mutant
livin Antiapoptotic Adenocarcinoma
Livin/ML-IAP/KIAP(212)
MAPK #3
Matrix metalloproteinase (204)
MDM-2 (138)
MDR (142)
MDR Multidrug resistance Adenocarcinoma (Hela cells)
MMP-9,cathepsin B
MYC #3
NFκB p65
Nox1 Superoxide-generating oxidase Transformed NRK cellsa
NPM-ALK (218)
p53 #3
Philadelphia chromosome Chronic myeloid leukemia
PKC-α (138)
PLK 1
PLK1 (214)
Rho C Cell motility Metastasis
Ribonucleotide reductase Gemcitabine resistance Hepatic metastasis
RRM2
S100A10 (216)
STAT3 (217)
Survivin
survivin Antiapoptotic Adenocarcinoma (Hela cells)
Telomerase (215)
TEL-PDGFbeaR #3
TEL-PDGFβR
TGF-β (138)
u-PA #3
VEGF
VEGF (53, 138)
β-Catenin
Skp-2 #4
P110a,P110b of PI 3 kinase #8
Wt1,Pax2,Wnt4 #8